We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Harmony Biosciences, Acadia Pharmaceuticals, Biogen, Insmed and Agios Pharmaceuticals
Read MoreHide Full Article
For Immediate Release
Chicago, IL – July 28, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Harmony Biosciences (HRMY - Free Report) , Acadia Pharmaceuticals (ACAD - Free Report) , Biogen (BIIB - Free Report) , Insmed (INSM - Free Report) and Agios Pharmaceuticals (AGIO - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?
The second-quarter 2026 reporting cycle for the Medical sector is picking up pace. The sector primarily comprises pharma/biotech and medical device companies.
The earnings season for the Medical sector kicked off earlier this month when pharma bellwether Johnson & Johnson posted encouraging earnings results. J&J also raised its 2026 outlook for the second time this year, driven by the strong performance of its Innovative Medicines/Pharma segment. Another large-cap company that recently reported impressive earnings results was Novartis, driven by strong demand for key growth brands.
The Earnings Trends report indicates that, as of July 22, 10.2% of the companies in the Medical sector, representing about 25% of the sector’s market capitalization, have reported quarterly earnings. So far, all participants have outperformed both earnings and revenues. While earnings rose 14.6% year over year, sales increased 2.3%. Overall, second-quarter earnings are expected to fall 17.4% year over year, while revenues are expected to rise 5.2%.
Zeroing in on Winners
We have highlighted five biotech companies — Harmony Biosciences, Acadia Pharmaceuticals, Biogen, Insmed and Agios Pharmaceuticals — that are expected to deliver a beat in their upcoming quarterly results.
Earnings ESP is our proprietary methodology for determining the stocks with the best chance of delivering an earnings surprise. It shows the percentage difference between the Most Accurate Estimate and the Zacks Consensus Estimate.
According to the Zacks model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. The selection can be made with the help of the Zacks Stock Screener.
Our research shows that the chance of an earnings surprise for stocks with this combination is as high as 70%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
5 Biotech Stocks That Match the Criteria
Harmony Biosciences
HRMY is a commercial-stage company that develops and commercializes therapies for sleep/wake disorders and rare neurological diseases. The company has an Earnings ESP of +14.14% and a Zacks Rank #1 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for second-quarter earnings is pegged at 97 cents per share.
Harmony Biosciences missed on earnings in each of the trailing four quarters, delivering an average negative surprise of 25.16%. It is scheduled to report earnings on Aug. 4, before the opening bell.
A commercial-stage company, ACAD, is focused on developing and marketing therapies for central nervous system disorders and rare diseases. The company has an Earnings ESP of +25.00% and a Zacks Rank #2 at present. The Zacks Consensus Estimate for second-quarter earnings is pegged at 6 cents per share.
Acadia Pharmaceuticals beat on earnings in three of the trailing four quarters and missed the mark on one occasion, delivering an average surprise of 20.83%. The company is scheduled to release results on Aug. 4, after the market closes.
BIIB is one of the world’s leading biotechs, focusing on developing innovative therapies for treating serious neurological and neurodegenerative diseases. The company has an Earnings ESP of +220.79% and a Zacks Rank #3 at present. The Zacks Consensus Estimate for second-quarter earnings is pegged at 94 cents per share.
Biogen beat on earnings in each of the trailing four quarters, delivering an average surprise of 26.87%. It is scheduled to report earnings on July 29, before the opening bell.
INSM is a commercial-stage biopharmaceutical company focused on the development of therapies targeting serious and rare indications. The company has an Earnings ESP of +22.32% and a Zacks Rank #3 at present. The Zacks Consensus Estimate for second-quarter earnings is pegged at a loss of 69 cents per share.
Insmed missed on earnings in three of the trailing four quarters and beat the mark on one occasion, delivering an average negative surprise of 22.93%. The company is scheduled to release results on Aug. 6, before the opening bell.
AGIO is a biopharmaceutical company focused on the development of treatments for rare genetic metabolic disorders, a subset of orphan genetic metabolic diseases. The company has an Earnings ESP of +12.67% and a Zacks Rank #3 at present. The Zacks Consensus Estimate for second-quarter earnings is pegged at a loss of $1.86 per share.
Agios beat on earnings in three of the trailing four quarters and missed the mark on one occasion, delivering an average surprise of 2.39%. It is scheduled to report earnings on July 30, before the opening bell.
Free: Instant Access to Zacks' Market-Crushing Strategies
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can tap into those powerful strategies – and the high-potential stocks they uncover – free. No strings attached.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
View the Zacks #1 Rank List
Image: Bigstock
The Zacks Analyst Blog Highlights Harmony Biosciences, Acadia Pharmaceuticals, Biogen, Insmed and Agios Pharmaceuticals
For Immediate Release
Chicago, IL – July 28, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Harmony Biosciences (HRMY - Free Report) , Acadia Pharmaceuticals (ACAD - Free Report) , Biogen (BIIB - Free Report) , Insmed (INSM - Free Report) and Agios Pharmaceuticals (AGIO - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?
The second-quarter 2026 reporting cycle for the Medical sector is picking up pace. The sector primarily comprises pharma/biotech and medical device companies.
The earnings season for the Medical sector kicked off earlier this month when pharma bellwether Johnson & Johnson posted encouraging earnings results. J&J also raised its 2026 outlook for the second time this year, driven by the strong performance of its Innovative Medicines/Pharma segment. Another large-cap company that recently reported impressive earnings results was Novartis, driven by strong demand for key growth brands.
The Earnings Trends report indicates that, as of July 22, 10.2% of the companies in the Medical sector, representing about 25% of the sector’s market capitalization, have reported quarterly earnings. So far, all participants have outperformed both earnings and revenues. While earnings rose 14.6% year over year, sales increased 2.3%. Overall, second-quarter earnings are expected to fall 17.4% year over year, while revenues are expected to rise 5.2%.
Zeroing in on Winners
We have highlighted five biotech companies — Harmony Biosciences, Acadia Pharmaceuticals, Biogen, Insmed and Agios Pharmaceuticals — that are expected to deliver a beat in their upcoming quarterly results.
Earnings ESP is our proprietary methodology for determining the stocks with the best chance of delivering an earnings surprise. It shows the percentage difference between the Most Accurate Estimate and the Zacks Consensus Estimate.
According to the Zacks model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. The selection can be made with the help of the Zacks Stock Screener.
Our research shows that the chance of an earnings surprise for stocks with this combination is as high as 70%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
5 Biotech Stocks That Match the Criteria
Harmony Biosciences
HRMY is a commercial-stage company that develops and commercializes therapies for sleep/wake disorders and rare neurological diseases. The company has an Earnings ESP of +14.14% and a Zacks Rank #1 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for second-quarter earnings is pegged at 97 cents per share.
Harmony Biosciences missed on earnings in each of the trailing four quarters, delivering an average negative surprise of 25.16%. It is scheduled to report earnings on Aug. 4, before the opening bell.
Harmony Biosciences Holdings, Inc. price-eps-surprise | Harmony Biosciences Holdings, Inc. Quote
Acadia Pharmaceuticals
A commercial-stage company, ACAD, is focused on developing and marketing therapies for central nervous system disorders and rare diseases. The company has an Earnings ESP of +25.00% and a Zacks Rank #2 at present. The Zacks Consensus Estimate for second-quarter earnings is pegged at 6 cents per share.
Acadia Pharmaceuticals beat on earnings in three of the trailing four quarters and missed the mark on one occasion, delivering an average surprise of 20.83%. The company is scheduled to release results on Aug. 4, after the market closes.
ACADIA Pharmaceuticals Inc. price-eps-surprise | ACADIA Pharmaceuticals Inc. Quote
Biogen
BIIB is one of the world’s leading biotechs, focusing on developing innovative therapies for treating serious neurological and neurodegenerative diseases. The company has an Earnings ESP of +220.79% and a Zacks Rank #3 at present. The Zacks Consensus Estimate for second-quarter earnings is pegged at 94 cents per share.
Biogen beat on earnings in each of the trailing four quarters, delivering an average surprise of 26.87%. It is scheduled to report earnings on July 29, before the opening bell.
Biogen Inc. price-eps-surprise | Biogen Inc. Quote
Insmed
INSM is a commercial-stage biopharmaceutical company focused on the development of therapies targeting serious and rare indications. The company has an Earnings ESP of +22.32% and a Zacks Rank #3 at present. The Zacks Consensus Estimate for second-quarter earnings is pegged at a loss of 69 cents per share.
Insmed missed on earnings in three of the trailing four quarters and beat the mark on one occasion, delivering an average negative surprise of 22.93%. The company is scheduled to release results on Aug. 6, before the opening bell.
Insmed, Inc. price-eps-surprise | Insmed, Inc. Quote
Agios Pharmaceuticals
AGIO is a biopharmaceutical company focused on the development of treatments for rare genetic metabolic disorders, a subset of orphan genetic metabolic diseases. The company has an Earnings ESP of +12.67% and a Zacks Rank #3 at present. The Zacks Consensus Estimate for second-quarter earnings is pegged at a loss of $1.86 per share.
Agios beat on earnings in three of the trailing four quarters and missed the mark on one occasion, delivering an average surprise of 2.39%. It is scheduled to report earnings on July 30, before the opening bell.
Agios Pharmaceuticals, Inc. price-eps-surprise | Agios Pharmaceuticals, Inc. Quote
Free: Instant Access to Zacks' Market-Crushing Strategies
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can tap into those powerful strategies – and the high-potential stocks they uncover – free. No strings attached.
Get all the details here >>
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.